Markets

RH (NYSE: RH) will release its second-quarter fiscal 2025 earnings on September 11, 2025, after market close. A letter from Chairman and CEO Gary Friedman and the full financial results will be available on the investor relations website at ir.rh.com. A live conference call and webcast will be held at 2:00 pm Pacific Time, offering further insights. Analysts will focus on supply chain, pricing, product performance, and expansion efforts. RH operates as a curator of design in the luxury lifestyle market.

The FLAURA2 Phase III trial demonstrated that TAGRISSO® (osimertinib) combined with chemotherapy significantly improved overall survival (OS) compared to TAGRISSO monotherapy in 1st-line EGFRm NSCLC. The combination therapy achieved a median OS of 47.5 months versus 37.6 months with monotherapy, reducing the risk of death by 23%. The safety profile was manageable, reinforcing TAGRISSO as a standard of care and backbone therapy across EGFRm lung cancer stages.

Nuvalent has initiated a rolling NDA submission to the FDA for zidesamtinib, a ROS1-selective inhibitor, for advanced ROS1-positive NSCLC patients previously treated with TKIs. The submission is supported by pivotal data from the ARROS-1 trial presented at WCLC 2025. Zidesamtinib has been granted RTOR designation, potentially accelerating its review. The drug is designed to overcome resistance mutations and improve treatment of brain metastases. Completion of the rolling submission is expected in Q3 2025. Nuvalent is also in discussion with the FDA regarding potential expansion of indications.

Douyin, the Chinese version of TikTok, is combating fraud targeting users of its mobile phone recharge service. A data leak stemming from vendor supply chain issues led to phishing scams where users were pressured to refund “errors.” Douyin has removed 25 non-compliant vendors, freezing their payments and blacklisting them. The incident highlights the need for stricter vendor due diligence, data security, and monitoring to maintain user trust and a secure e-commerce environment.

Summit Therapeutics announced positive Phase III HARMONi trial data for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients who progressed after EGFR-TKI treatment. While the primary analysis showed a positive OS trend (HR=0.79, p=0.057), longer follow-up of Western patients demonstrated improved OS (HR=0.78, p=0.0332). North American patients showed a promising OS HR of 0.70. Ivonescimab’s safety profile was consistent with prior studies. A conference call will be held September 8, 2025, to discuss these findings.

A vehicle displaying a “ghost face” mask sparked a police investigation in Hebei, China, to determine if it violated traffic laws. This follows a similar incident in Hangzhou where people wore masks to scare drivers. Authorities are concerned about distractions on the road, prompting legal consideration of objects obstructing driver visibility. The incident, documented via social media, highlights the tension between harmless pranks, public safety, and the legal ramifications of disruptive behavior, raising broader questions about road safety and public conduct.

Recent rumors in China link rooftop solar panels with increased cancer rates and birth defects, causing public concern. Experts measured radiation from various devices, including solar panels, finding levels significantly below national safety standards (less than 20 nanoteslas compared to the 100 microteslas limit). They clarified that while solar panels emit radiation, like most electronics, the levels are harmless. Experts emphasized that household appliances meet safety regulations, reassuring the public and supporting China’s renewable energy goals amid misinformation.

A Chinese delivery driver unknowingly transported a live crocodile, sparking online debate about logistics platform regulations. The sender allegedly claimed the crocodile was dead, but it revived en route, damaging the driver’s footwear. Lalamove stated the sender failed to specify the cargo, and the driver didn’t cancel the order, but a compensation agreement was reached. The incident highlights risks within the on-demand delivery sector concerning proper goods verification and the need for clearer guidelines for both senders and drivers.

At IFA 2025, GlocalMe unveiled its “3-3-5 Digital Inclusion Framework” to address the global digital divide. This initiative focuses on bridging three gaps between carrier networks, local/international access, and human-pet connectivity. It’s powered by CloudSIM®, AI HyperConn®, and a positioning system, and realized through five product lines including Pet Network (PetPhone), Personal Mobile Network (eSIM Trio), Travel Network (Numen Air, MeowGo G40 Pro, G50 Pro), Life Network (UniCord Pro, RoamPlug), and Home Network (GuardFlex Pro). GlocalMe emphasizes both 5G and 4G coverage, leveraging AI to optimize connectivity performance and cost.

Grandma Xu, a Chinese senior and former fraud victim, successfully turned the tables on a scammer impersonating her grandson. Educated by local police anti-fraud campaigns, she skillfully engaged the suspect until authorities arrived. This case highlights the growing success of anti-fraud education in empowering seniors to identify and thwart scams targeting their trust and vulnerabilities. Authorities emphasize vigilance, communication with family, and reporting suspicious activity to combat increasingly sophisticated schemes that exploit elders.